Anders Boyd1, Sarah Maylin2,3,4, Raoul Moh5, Nadia Mahjoub2,3, Delphine Gabillard6,7, Serge Paul Eholié8,5,9, Christine Danel6,7,5, Xavier Anglaret6,7,5, Fabien Zoulim10, Pierre-Marie Girard11,12, Constance Delaugerre2,3,4, Karine Lacombefor. 1. INSERM, UMR_S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France. 2. Laboratoire de Virologie, Hôpital Saint-Louis, AP-HP, Paris, France. 3. INSERM U941, Paris, France. 4. Université Paris-Diderot, Paris, France. 5. Programme PAC-CI, ANRS Research Site, Treichville University Hospital, Abidjan, Ivory Coast. 6. Epidémiologie-Biostatistique, INSERM, U897. 7. ISPED, University of Bordeaux, Bordeaux, France. 8. Medical School, University Felix Houphouet Boigny, Abidjan, Côte d'Ivoire. 9. Department of Infectious and Tropical Diseases, Treichville University Teaching Hospital, Abidjan, Ivory Coast. 10. Centre de Recherche sur le Cancer de Lyon, Equipes 15 et 16, INSERM, Unité 1052, Lyon, France. 11. Department of Infectious and Tropical Diseases, Saint-Antoine Hospital, Paris, France. 12. Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Universités, UPMC Univ Paris 06, UMR S 1136, Paris, France.
Abstract
BACKGROUND AND AIM: In Sub-Saharan Africa, seroclearance of hepatitis B surface antigen (HBsAg) and hepatitis B "e" antigen (HBeAg), including their quantifiable markers, have rarely been evaluated during long-term antiviral treatment among patients coinfected with HIV and hepatitis B virus (HBV). METHODS: In this prospective cohort study from two randomized-control trials in Côte d'Ivoire, 161 antiretroviral-naïve HIV-HBV coinfected patients starting lamivudine (n = 76) or tenofovir/emtricitabine (n = 85) containing antiretroviral therapy were included. HBV DNA was quantified using an in-house assay (detection limit = 12 copies/mL) and HBsAg quantification (qHBsAg) using the Elecsys assay. RESULTS: Overall, 33 (20.5%) patients were HBeAg positive, 121 (75.2%) had detectable HBV DNA, and 92/93 (98.9%) harbored HBV genotype E. Median treatment duration was 35.5 months (interquartile range: 24.3-36.4). Among HBeAg-positive patients, cumulative proportion with HBeAg seroclearance was 46.3% (n = 14). Overall, cumulative proportion of HBsAg seroclearance was 6.6% (n = 10). Lower baseline qHBsAg levels and strong 12-month declines in qHBsAg were significantly associated with HBsAg seroclearance for both HBeAg-negative and HBeAg-positive patients. When taken at certain levels, these determinants provided moderate sensitivity (Se) and specificity (Sp) in predicting HBsAg seroclearance at month 36 (≤ 1000 IU/mL at baseline, Se = 0.80, Sp = 0.80; ≥ 1.0 log10 IU/mL drop at month 12, Se = 0.57, Sp = 1.00). Instead, qHBsAg levels ≤ 100 or ≤ 10 IU/mL at month 12 were optimal (both Se = 0.90 and Sp = 1.00). Detectable HBV-DNA provided fairly high Se and Sp when evaluated at baseline (Se = 1.00, Sp = 0.80), but not at month 12 (Se = 0.80, Sp = 0.40). CONCLUSIONS: HBsAg seroclearance rates are not common in patients from Sub-Saharan Africa treated with anti-HBV containing antiretroviral therapy. qHBsAg levels at 12 months of treatment may accurately predict HBsAg seroclearance.
BACKGROUND AND AIM: In Sub-Saharan Africa, seroclearance of hepatitis B surface antigen (HBsAg) and hepatitis B "e" antigen (HBeAg), including their quantifiable markers, have rarely been evaluated during long-term antiviral treatment among patients coinfected with HIV and hepatitis B virus (HBV). METHODS: In this prospective cohort study from two randomized-control trials in Côte d'Ivoire, 161 antiretroviral-naïve HIV-HBV coinfectedpatients starting lamivudine (n = 76) or tenofovir/emtricitabine (n = 85) containing antiretroviral therapy were included. HBV DNA was quantified using an in-house assay (detection limit = 12 copies/mL) and HBsAg quantification (qHBsAg) using the Elecsys assay. RESULTS: Overall, 33 (20.5%) patients were HBeAg positive, 121 (75.2%) had detectable HBV DNA, and 92/93 (98.9%) harbored HBV genotype E. Median treatment duration was 35.5 months (interquartile range: 24.3-36.4). Among HBeAg-positive patients, cumulative proportion with HBeAg seroclearance was 46.3% (n = 14). Overall, cumulative proportion of HBsAg seroclearance was 6.6% (n = 10). Lower baseline qHBsAg levels and strong 12-month declines in qHBsAg were significantly associated with HBsAg seroclearance for both HBeAg-negative and HBeAg-positive patients. When taken at certain levels, these determinants provided moderate sensitivity (Se) and specificity (Sp) in predicting HBsAg seroclearance at month 36 (≤ 1000 IU/mL at baseline, Se = 0.80, Sp = 0.80; ≥ 1.0 log10 IU/mL drop at month 12, Se = 0.57, Sp = 1.00). Instead, qHBsAg levels ≤ 100 or ≤ 10 IU/mL at month 12 were optimal (both Se = 0.90 and Sp = 1.00). Detectable HBV-DNA provided fairly high Se and Sp when evaluated at baseline (Se = 1.00, Sp = 0.80), but not at month 12 (Se = 0.80, Sp = 0.40). CONCLUSIONS: HBsAg seroclearance rates are not common in patients from Sub-Saharan Africa treated with anti-HBV containing antiretroviral therapy. qHBsAg levels at 12 months of treatment may accurately predict HBsAg seroclearance.
Authors: Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Motswedi Anderson; Simani Gaseitsiwe; Sikhulile Moyo; Kerapetse P Thami; Terence Mohammed; Ditiro Setlhare; Theresa K Sebunya; Eleanor A Powell; Joseph Makhema; Jason T Blackard; Richard Marlink; Max Essex; Rosemary M Musonda Journal: Open Forum Infect Dis Date: 2016-08-16 Impact factor: 3.835
Authors: Pierre Gantner; Laurent Cotte; Clotilde Allavena; Firouzé Bani-Sadr; Thomas Huleux; Claudine Duvivier; Marc-Antoine Valantin; Christine Jacomet; Véronique Joly; Antoine Chéret; Pascal Pugliese; Pierre Delobel; André Cabié; David Rey Journal: PLoS One Date: 2019-04-18 Impact factor: 3.240
Authors: Bright Nsokolo; Anne Kanunga; Edford Sinkala; Kanekwa Zyambo; Dia Kumwenda; David Chama; Gabriel Muyinda; Michael Vinikoor; Samreen Ijaz; Richard Tedder; Ali Khalifa A Elmdaah; Meleri Jones; Clarence Chiluba; Victor Mudenda; Robert D Goldin; Graham Foster; Paul Kelly Journal: Trans R Soc Trop Med Hyg Date: 2017-09-01 Impact factor: 2.184